ArticleCancer discovery2021
Resolving the Spatial and Cellular Architecture of Lung Adenocarcinoma by Multiregion Single-Cell Sequencing.
Open access · greenAbstract read
In one paragraph
Article in Cancer discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers.
0numbers the graph read from it
0cells of the map it votes in
100citing papers in PubMed
8.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
100 citing papers in PubMed, 128 citations in OpenAlex.
- Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: 3-year survival update and multi-omics analysis.Clinical and translational medicine · 2025Trial
- Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial.Nature medicine · 2023Trial
- Development and Validation of a Prognostic Nomogram for Lung Adenocarcinoma: A Population-Based Study.Journal of healthcare engineering · 2022Trial
- Multifocal ground-glass opacities in lung cancer: a narrative review of genomic evolution, immune ecology, and biology-informed clinical management.Journal of thoracic disease · 2026Review
- Identifying Epithelial-Cell Progression Signatures (ECPSs) from Multi-Resolution Multi-Omics Data for Translational Clinical Applications in Lung Adenocarcinoma.International journal of molecular sciences · 2026Article
- Tumor evolution: signaling pathways, molecular mechanisms and therapeutic targets.Signal transduction and targeted therapy · 2026Review
- Machine learning-driven development of a novel unfolded protein response-related gene signature for predicting lung adenocarcinoma patient prognosis.BMC cancer · 2026Article
- Cancer signaling networks in tumor progression and drug resistance: Crosstalk, adaptive reprogramming and therapeutic targeting (Review).Oncology reports · 2026Review
- FLT3L-secreting cDC1 in situ vaccination enhances antitumor immunity and synergizes with PD-1 blockade in murine non-small cell lung cancer.Journal for immunotherapy of cancer · 2026Article
- Integrated multi-omics profiling of treatment-naive cervix uteri premalignant lesions and cervical squamous cell carcinoma reveals ecosystem and drivers underlying cervical cancer progression.Cell death & disease · 2026Article
- Heterogeneity of macrophages in PD-1/PD-L1 inhibitor therapy: a single-cell perspective.Cellular & molecular biology letters · 2026Review
- Loss of miR-29a/b1 Cluster Reprograms the Tumor Microenvironment and Contributes to Immunosuppression in Lung Cancer.Cancer immunology research · 2026Article
- Pan-cancer spatial atlas of tertiary lymphoid structures.Science (New York, N.Y.) · 2026Article
- Anticancer Treatment Influences TREM2 in Tumor-Associated Macrophages in Lung Cancer.Cancer research and treatment · 2026Article
- Enhanced antitumor efficacy of combined targeting of adenosine ACancer immunology, immunotherapy : CII · 2026Article
- The Fibro-Immune Landscape Across Organs: A Single-Cell Comparative Study of Human Fibrotic Diseases.International journal of molecular sciences · 2026Article
- Multimodal spatial-omics reveal co-evolution of alveolar progenitors and proinflammatory niches in progression of lung precursor lesions.Cancer cell · 2026Article
- Defining the cellular and molecular identities of histologic subtypes in lung adenocarcinoma.Experimental hematology & oncology · 2026Article
- Article
- iPSC-derived CAR-NK extracellular vesicles for non-small cell lung cancer: evidence, engineering, and translational barriers.Frontiers in immunology · 2026Review
40 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
42 authors at 6 institutions in 3 countries.
Ansam Sinjab *Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-5777-227X
Guangchun Han *Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Warapen TreekitkarnmongkolDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-7542-5201
Kieko HaraDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Patrick M BrennanDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-9068-4527
Minghao DangDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Dapeng HaoDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-9043-371X
Ruiping WangDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-9380-0266
Enyu DaiDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Hitoshi DejimaDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-2401-4357
Jiexin ZhangDepartment of Bioinformatics and Computer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-9526-6730
Elena BogatenkovaDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Beatriz Sanchez-EspiridionDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Kyle ChangDepartment of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Danielle R LittleDepartment of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-7262-1496
Samer BazziFaculty of Arts and Sciences, University of Balamand, Koura, Lebanon.
Linh M TranDepartment of Medicine, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0001-8597-643X
Kostyantyn KrysanDepartment of Medicine, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0003-0250-1346
Carmen BehrensDepartment of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-1905-8061
Dzifa Y DuoseDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Edwin R ParraDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-9068-1636
Maria Gabriela RasoDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Luisa M SolisDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-1253-630X
Junya FukuokaDepartment of Pathology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Jianjun ZhangDepartment of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-9526-6730
Boris SepesiDepartment of Cardiovascular and Thoracic Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Tina CasconeDepartment of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Lauren Averett ByersDepartment of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-0780-2677
Don L GibbonsDepartment of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jichao ChenDepartment of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Seyed Javad MoghaddamDepartment of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Edwin J OstrinDepartment of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-4538-6539
Daniel RosenDepartment of Pathology and Immunology, Baylor College of Medicine, Houston, Texas.
John V HeymachDepartment of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-9068-8942
Paul ScheetDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Steven M DubinettDepartment of Medicine, University of California, Los Angeles, Los Angeles, California.
Junya FujimotoDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Ignacio I WistubaDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Christopher S StevensonLung Cancer Initiative at Johnson and Johnson, Boston, Massachusetts.
Avrum SpiraLung Cancer Initiative at Johnson and Johnson, Boston, Massachusetts.
Linghua WangDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. hkadara@mdanderson.org lwang22@mdanderson.org.ORCID 0000-0001-9380-0266
Humam KadaraDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas. hkadara@mdanderson.org lwang22@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USUniversity of California, Los Angeles · USJohnson & Johnson (United States) · USBaylor College of Medicine · USUniversity of Balamand · LBUniversity of Nagasaki · JP
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MUNIVERSITY OF TEXAS--SPORE IN LUNG CANCERP50CA070907 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HEYMACH, JOHN V., MINNA, JOHN D. · 1996 to 2024
$57.4MThe Lung PCA: A Multi-Dimensional Atlas of Pulmonary PremalignancyU2CCA233238 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI SPIRA, AVRUM E · 2018 to 2021
$7.0MRole of AT1 cells in perinatal lung maturationR01HL130129 · NHLBI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CHEN, JICHAO · 2016 to 2023
$4.1MTranscriptional and epigenetic basis of lung epithelial cell fateR01HL153511 · NHLBI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CHEN, JICHAO · 2020 to 2023
$2.5M(PQ1) Progression of the airway field of injury to Kras mutant lung cancerR01CA205608 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KADARA, HUMAM, SCHEET, PAUL A · 2016 to 2019
$1.4MNovaSeq6000S10OD024977 · OD · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HUFF, VICKI · 2018 to 2018
$995kCSRD VA I01 CX000345NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA070907NCI NIH HHS R01 CA205608NCI NIH HHS U2C CA233238NHLBI NIH HHS R01 HL130129NHLBI NIH HHS R01 HL153511NIH HHS S10 OD024977
Abstract
Little is known of the geospatial architecture of individual cell populations in lung adenocarcinoma (LUAD) evolution. Here, we perform single-cell RNA sequencing of 186,916 cells from five early-stage LUADs and 14 multiregion normal lung tissues of defined spatial proximities from the tumors. We show that cellular lineages, states, and transcriptomic features geospatially evolve across normal regions to LUADs. LUADs also exhibit pronounced intratumor cell heterogeneity within single sites and transcriptional lineage-plasticity programs. T regulatory cell phenotypes are increased in normal tissues with proximity to LUAD, in contrast to diminished signatures and fractions of cytotoxic CD8
Indexed as
CD8-Positive T-LymphocytesTumor MicroenvironmentAdenocarcinoma of LungHumansLung NeoplasmsSingle-Cell Analysis
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.